948 related articles for article (PubMed ID: 26000842)
21. CRISPR: gene editing is just the beginning.
Ledford H
Nature; 2016 Mar; 531(7593):156-9. PubMed ID: 26961639
[No Abstract] [Full Text] [Related]
22. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
Jo YI; Suresh B; Kim H; Ramakrishna S
Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
[TBL] [Abstract][Full Text] [Related]
23. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
[TBL] [Abstract][Full Text] [Related]
24. Expanding the CRISPR Toolbox with ErCas12a in Zebrafish and Human Cells.
Wierson WA; Simone BW; WareJoncas Z; Mann C; Welker JM; Kar B; Emch MJ; Friedberg I; Gendron WAC; Barry MA; Clark KJ; Dobbs DL; McGrail MA; Ekker SC; Essner JJ
CRISPR J; 2019 Dec; 2(6):417-433. PubMed ID: 31742435
[TBL] [Abstract][Full Text] [Related]
25. The crystal structure of Cpf1 in complex with CRISPR RNA.
Dong D; Ren K; Qiu X; Zheng J; Guo M; Guan X; Liu H; Li N; Zhang B; Yang D; Ma C; Wang S; Wu D; Ma Y; Fan S; Wang J; Gao N; Huang Z
Nature; 2016 Apr; 532(7600):522-6. PubMed ID: 27096363
[TBL] [Abstract][Full Text] [Related]
26. Implementation of the CRISPR-Cas9 system in fission yeast.
Jacobs JZ; Ciccaglione KM; Tournier V; Zaratiegui M
Nat Commun; 2014 Oct; 5():5344. PubMed ID: 25352017
[TBL] [Abstract][Full Text] [Related]
27. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
Yang H; Patel DJ
Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
[TBL] [Abstract][Full Text] [Related]
28. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection.
East-Seletsky A; O'Connell MR; Knight SC; Burstein D; Cate JH; Tjian R; Doudna JA
Nature; 2016 Oct; 538(7624):270-273. PubMed ID: 27669025
[TBL] [Abstract][Full Text] [Related]
29. CRISPR Mediated Genome Engineering and its Application in Industry.
Kaboli S; Babazada H
Curr Issues Mol Biol; 2018; 26():81-92. PubMed ID: 28879858
[TBL] [Abstract][Full Text] [Related]
30. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of stringent PAM recognition by CRISPR-C2c1 in complex with sgRNA.
Wu D; Guan X; Zhu Y; Ren K; Huang Z
Cell Res; 2017 May; 27(5):705-708. PubMed ID: 28374750
[No Abstract] [Full Text] [Related]
32. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
33. Applications of CRISPR Genome Engineering in Cell Biology.
Wang F; Qi LS
Trends Cell Biol; 2016 Nov; 26(11):875-888. PubMed ID: 27599850
[TBL] [Abstract][Full Text] [Related]
34. Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs.
Port F; Bullock SL
Nat Methods; 2016 Oct; 13(10):852-4. PubMed ID: 27595403
[TBL] [Abstract][Full Text] [Related]
35. Methods in Enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specific genome alterations. Preface.
Doudna JA; Sontheimer EJ
Methods Enzymol; 2014; 546():xix-xx. PubMed ID: 25398356
[No Abstract] [Full Text] [Related]
36. A Survey of Genome Editing Activity for 16 Cas12a Orthologs.
Zetsche B; Abudayyeh OO; Gootenberg JS; Scott DA; Zhang F
Keio J Med; 2020 Sep; 69(3):59-65. PubMed ID: 31723075
[TBL] [Abstract][Full Text] [Related]
37. Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii.
Shen B; Brown K; Long S; Sibley LD
Methods Mol Biol; 2017; 1498():79-103. PubMed ID: 27709570
[TBL] [Abstract][Full Text] [Related]
38. Mouse genome engineering via CRISPR-Cas9 for study of immune function.
Pelletier S; Gingras S; Green DR
Immunity; 2015 Jan; 42(1):18-27. PubMed ID: 25607456
[TBL] [Abstract][Full Text] [Related]
39. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
40. Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9.
Fu BXH; Smith JD; Fuchs RT; Mabuchi M; Curcuru J; Robb GB; Fire AZ
Nat Microbiol; 2019 May; 4(5):888-897. PubMed ID: 30833733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
